- Trials with a EudraCT protocol (33)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
33 result(s) found for: Critical mass.
Displaying page 1 of 2.
EudraCT Number: 2016-003557-15 | Sponsor Protocol Number: HMB-ICU | Start Date*: 2018-08-31 | |||||||||||
Sponsor Name:Guy's and St Thomas NHS Foundation Trust | |||||||||||||
Full Title: A Study to Investigate the Effect of β-Hydroxy-β-Methylbutyrate (HMB) on Skeletal Muscle Wasting in Early Critical Illness. | |||||||||||||
Medical condition: Critical illness | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-004978-34 | Sponsor Protocol Number: RBHP2017BACHOUMAS | Start Date*: 2018-12-04 |
Sponsor Name:CHU de Clermont-ferrand | ||
Full Title: Efficacy of Testosterone gel to restore normal serum values of testosterone during the acute phase of critical illness in adult ICU patients. An open-label parallel randomized controlled pilot study | ||
Medical condition: - Hypermetabolism in ICU, loss of muscle mass and functional disability after ICU - ICU acquired hypogonadism - Treatment with testosterone gel in ICU | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2007-006445-41 | Sponsor Protocol Number: CTSSTS1010207V2 | Start Date*: 2012-01-28 | |||||||||||
Sponsor Name:HEALTH RICERCAE SVILUPPO SRL | |||||||||||||
Full Title: The irreversibility of hemorrhagic shock treatment with anti-opiod neuropeptide | |||||||||||||
Medical condition: Mortality of hemorrhagic shock grade 2 and 3 is from 50 to '80% in the first 24 hours, and morbidity and mortality betrayed is to 7 to 8 days of' 90% for Acute Respiratory Distress Syndrome and / o... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2004-000539-27 | Sponsor Protocol Number: CLAF237A2307 | Start Date*: 2004-09-08 |
Sponsor Name:Novartis Sverige AB | ||
Full Title: A Multicenter, Double-Blind, Randomized, Parallel-Group Study to Compare the Effect of 52 Weeks Treatment with LAF237 50 mg qd to Placebo in Drug-Naïve Patients with Type 2 Diabetes and Mild Hyperg... | ||
Medical condition: Type 2 Diabetes | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: SE (Completed) FI (Completed) ES (Completed) | ||
Trial results: View results |
EudraCT Number: 2004-000235-28 | Sponsor Protocol Number: 190-060 | Start Date*: 2004-10-27 |
Sponsor Name:Sepracor Inc. | ||
Full Title: The effects of a single evening dose of 3mg eszopiclone on next day driving ability and psychomotor/memory function in patients with primary insomnia compared to placebo | ||
Medical condition: Insomnia | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2004-000542-20 | Sponsor Protocol Number: CLAF237A2338 | Start Date*: 2004-07-16 | |||||||||||
Sponsor Name:NOVARTIS FARMA | |||||||||||||
Full Title: A Multicenter, Double-Blind, Randomized, Active Controlled Study to Compare the Effect of 52 Weeks Treatment with LAF237 50 mg bid to Gliclazide up to 320 mg Daily as Add-On Therapy in Patients wit... | |||||||||||||
Medical condition: treatment of type 2 diabetes in combination therapy with other anti-diabetic oral drugs | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) SK (Completed) ES (Completed) DK (Completed) CZ (Completed) HU (Completed) GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2022-003268-25 | Sponsor Protocol Number: AT-03A-017 | Start Date*: 2023-05-12 | |||||||||||
Sponsor Name:Atea Pharmaceuticals, Inc. | |||||||||||||
Full Title: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Bemnifosbuvir in High-Risk Outpatients with COVID-19 | |||||||||||||
Medical condition: COVID-19 | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Trial now transitioned) ES (Ongoing) LV (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2004-000540-24 | Sponsor Protocol Number: CLAF237A2310 | Start Date*: 2004-12-15 |
Sponsor Name:Novartis Pharma Services AG | ||
Full Title: A multicenter, double-blind, randomized, active controlled study to compare the effect of long term treatment with LAF237 50 mg bid to gliclazide up to 320 mg daily in drug naïve patients with type... | ||
Medical condition: Type II Diabetes | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DK (Completed) IE (Completed) GB (Completed) DE (Completed) IT (Completed) ES (Completed) | ||
Trial results: View results |
EudraCT Number: 2018-002547-29 | Sponsor Protocol Number: ATB-203 | Start Date*: 2019-11-21 | ||||||||||||||||||||||||||
Sponsor Name:Atox Bio | ||||||||||||||||||||||||||||
Full Title: Phase 2 randomized, double-blind, placebo-controlled, parallel-group study to evaluate the safety and efficacy of Reltecimod as compared to placebo in addition to standard of care in patients with ... | ||||||||||||||||||||||||||||
Medical condition: Acute kidney injury due to intra-abdominal infection/sepsis | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: FR (Completed) BE (Prematurely Ended) NL (Prematurely Ended) | ||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2005-004636-52 | Sponsor Protocol Number: 2005AN005 | Start Date*: 2006-02-20 |
Sponsor Name:Heart of England NHS Foundation Trust | ||
Full Title: Randomised Double-Blind Placebo Controlled Trial of 40mg/day of Atorvastatin on Reduction in Severity of Sepsis in Ward Patients | ||
Medical condition: Sepsis is the clinical syndrome defined by the presence of both infection and a systemic inflammatory response. Sepsis is common in general medical and surgical wards with an estimated prevalence ... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (GB - no longer in EU/EEA) | ||
Trial results: (No results available) |
EudraCT Number: 2013-002078-30 | Sponsor Protocol Number: REDNES06052013 | Start Date*: 2013-08-08 |
Sponsor Name:Onze-Lieve-Vrouw Ziekenhuis | ||
Full Title: Acceleromyography and diaphragm electromyographic activity during neostigmine or sugammadex enhanced recovery from moderate residual neuromuscular blockade after rocuronium 0.6 mg kg-1: a double bl... | ||
Medical condition: We will compare usual care (neostigmine) with sugammadex for reversal of a moderate rocuronium-induced neuromuscular blockade and assess the effect on diaphragmatic EMG activity of sugammadex versu... | ||
Disease: | ||
Population Age: Adults | Gender: Male | |
Trial protocol: BE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2019-004599-20 | Sponsor Protocol Number: PHRCN_2018_BACHOUMAS | Start Date*: 2021-07-27 |
Sponsor Name:CHU DE CLERMONT-FERRAND | ||
Full Title: Effects of early testosterone gel administration on physical performance in the critically ill: a randomised double blind clinical trial | ||
Medical condition: Patients receiving invasive mechanical ventilation and treatment with a vasoactive drug within 96 hours of ICU admission will be screened. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2006-001812-65 | Sponsor Protocol Number: CVAL489K2301 | Start Date*: 2006-08-18 |
Sponsor Name:Novartis Pharma Services AG | ||
Full Title: A randomized, double-blind, placebo-controlled, parallel group, multicenter study to evaluate the effect of valsartan on proteinuria and glomerular filtration rate in children with Chronic Kidney D... | ||
Medical condition: Chronic kidney disease is characterized by a progressive decline of glomerular filtration rate (GFR), which occurs irrespectively of the cause of the renal damage once a critical nephron mass has b... | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2020-004488-14 | Sponsor Protocol Number: PDC01-0204 | Start Date*: 2021-02-10 | |||||||||||
Sponsor Name:Cessatech A/S | |||||||||||||
Full Title: Bioavailability study of intranasal sufentanil/ketamine fixed combination in healthy volunteers | |||||||||||||
Medical condition: Not applicable - healthy volunteers | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-001621-16 | Sponsor Protocol Number: 04516 | Start Date*: 2007-08-26 |
Sponsor Name:University College London (UCL) | ||
Full Title: An intergroup randomised trial of rituximab versus a watch and wait strategy in patients with advanced stage, asymptomatic, non-bulky fillicular lymphoma | ||
Medical condition: Advanced stage, asymptomatic, non-bulky follicular lymphoma (grades 1, 2 and 3a) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: CZ (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2006-000164-93 | Sponsor Protocol Number: 1000000 | Start Date*: 2006-05-10 |
Sponsor Name:Department of Anesthesiology University Hospital Center | ||
Full Title: Effect of Nutritional Support on Liver Integrity during General Anesthesia for Laparoscopic Cholecystectomy. A Pilot Study | ||
Medical condition: To the best of our knowledge, there is no clinical study on the protective effect of nutritional support on the liver in the perioperative setting using clinical and biological variables. Regarding... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: BE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2010-020763-20 | Sponsor Protocol Number: 10072DMcA-CS | Start Date*: 2010-10-04 |
Sponsor Name:National University of Ireland, Galway | ||
Full Title: Hydroxymethylglutaryl-CoA reductase inhibition with simvastatin in Acute lung injury to Reduce Pulmonary dysfunction (HARP 2) | ||
Medical condition: Acute lung injury | ||
Disease: | ||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |
Trial protocol: IE (Completed) GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2020-001304-42 | Sponsor Protocol Number: 20029 | Start Date*: 2020-08-24 | ||||||||||||||||
Sponsor Name:University of Nottingham | ||||||||||||||||||
Full Title: Efficacy of Nitric Oxide in Stroke -2 | ||||||||||||||||||
Medical condition: Hyperacute stroke - both ischaemic and haemorrhage | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-005462-30 | Sponsor Protocol Number: MDCO-APO-14-01 | Start Date*: 2016-10-26 |
Sponsor Name:The Medicines Company | ||
Full Title: A multiple dose, dose-finding, placebo controlled, double blind, randomized trial to compare the effect of treatment on plaque burden as determined by intravascular ultrasound and evaluate the effi... | ||
Medical condition: acute coronary syndrome | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: HU (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2015-000826-13 | Sponsor Protocol Number: MDCO-APO-15-01 | Start Date*: 2016-01-20 |
Sponsor Name:The Medicines Company | ||
Full Title: A placebo-controlled, double-blind, randomized trial to compare the effect of treatment on plaque burden as determined by intravascular ultrasound and to evaluate the efficacy, pharmacokinetics, sa... | ||
Medical condition: acute coronary syndrome | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: CZ (Completed) HU (Completed) NL (Completed) PL (Completed) | ||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
